Annexes

Annex 1. Agenda of the Guideline Development Group meeting

Co-chair: Nancy Santesso

Co-chair: Kelly Dooley

Time	Agenda item	Responsible
8:30–9:00	Registration
9:00–9:30	Welcome & introductions Meeting objective and agenda Declarations of interest	Karin Weyer
9:30–10:00	WHO requirements for evidence-based guidelines, GRADE methodology	Nancy Santesso
10:00–10:30	Global surveillance of resistance to isoniazid, pyrazinamide and fluoroquinolones	Matteo Zignol
10:30–11:00	Coffee break
11:00–11:45	Plenary—Presentation of IPD findings and GRADE tables from the Systematic reviews of Hr-TB regimen composition and duration	Dick Menzies, Federica Fregonese, McGill University, Canada
11:45–12:10	Plenary—Discussants present their perspectives on the implications of the findings for the approach to the composition and duration of Hr-TB regimens in adults and children	Discussants: Philipp du Cros (adults) and Farhana Amanullah (children).
12:10–12:25	Key issues relating to the PK/PD of anti-TB medicines of relevance to the Hr-TB treatment guidelines	Rada Savic & Michael Rich
12:25–12:45	Key issues relating to the detection of resistance to isoniazid, pyrazinamide and fluoroquinolones (molecular/phenotypic), and its relevance to the Hr-TB treatment guidelines	Daniela Cirillo
12:45–13:45	Lunch break
13:45–15:30	Plenary – Development of decision tables to formulate draft recommendation(s) based on certainty of the evidence, and other considerations (balance between desirable and undesirable effects, resources, feasibility, values and preferences, equity)	Co-chairs
15:30–16:00	Coffee break
16:00–17:45	Finalisation of draft recommendations and accompanying remarks	Facilitated discussion
17:45–18:00	Conclusion	Co-chairs

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third-party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “The translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Bookshelf ID: NBK531421

Contents

< Prev Next >

Bookshelf

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis [Internet].

Annexes

Annex 1. Agenda of the Guideline Development Group meeting

Views

Other titles in this collection

Recent Activity